Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 4/20 | 0.42 |
| ▸ | MPO | P05164 | 1/20 | 0.41 |
| ▸ | PDE2A | O00408 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.40 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.37 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31069725 | 1.00 | GPR3 (0.42) | GPR3MPOPDE2AADRB2FFAR4 | |
| SCHEMBL30553357 | 0.85 | PDE2A (0.44) | GPR3PDE2AFFAR4FFAR1TRPV1 | |
| SCHEMBL23780516 | 0.85 | PDE2A (0.44) | GPR3PDE2AFFAR4FFAR1TRPV1 | |
| SCHEMBL4550397 | 0.81 | MPO (0.44) | GPR3MPOPDE2AADRB2FFAR4 | |
| SCHEMBL20590929 | 0.81 | GPR3 (0.42) | GPR3MPOPDE2AADRB2FFAR4 | |
| SCHEMBL15599254 | 0.81 | PDE2A (0.44) | GPR3MPOPDE2AADRB2FFAR4 | |
| SCHEMBL10977660 | 0.81 | GPR3 (0.42) | GPR3MPOPDE2AADRB2FFAR4 | |
| SCHEMBL11030156 | 0.81 | FFAR4 (0.49) | GPR3MPOADRB2FFAR4ALKBH1 | |
| SCHEMBL2291338 | 0.81 | GPR3 (0.42) | GPR3PDE2AKIF11 | |
| SCHEMBL29786515 | 0.81 | MPO (0.44) | GPR3MPOPDE2AADRB2FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034108-A1 | SODIUM CHANNEL BLOCKERS | NOVARTIS AG (CH) | 2025-01-30 | — | — | US | disclosed |
| WO-2023143389-A1 | FUSED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL APPLICATION THEREOF | 江苏恒瑞医药股份有限公司 | 2023-08-03 | — | — | WO | disclosed |
| EP-3743430-B1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-112262139-B | Aminopyrrolotriazines as kinase inhibitors | 百时美施贵宝公司 | 2023-07-25 | — | — | CN | disclosed |
| US-11618753-B2 | Aminopyrrolotriazines as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-04-04 | — | — | US | disclosed |
| CN-112262139-A | Aminopyrrolotriazines as kinase inhibitors | 百时美施贵宝公司 | 2021-01-22 | — | — | CN | disclosed |
| EP-3743430-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2020-12-02 | — | — | EP | disclosed |
| US-20200347071-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-11-05 | — | — | US | disclosed |
| WO-2019147782-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-08-01 | — | — | WO | disclosed |
| US-10316035-B2 | Triazolopyridine inhibitors of myeloperoxidase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-06-11 | — | — | US | disclosed |
| US-20180244671-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2018-08-30 | — | — | US | disclosed |
| WO-2017040450-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-09 | — | — | WO | disclosed |
| US-20150072969-A1 | PHENYL ALKANOIC ACID DERIVATIVES AS GPR AGONISTS | Piramal Enterprises Limited (IN) | 2015-03-12 | — | — | US | disclosed |
| EP-2820005-A1 | PHENYL ALKANOIC ACID DERIVATIVES AS GPR AGONISTS | Piramal Enterprises Limited (IN) | 2015-01-07 | — | — | EP | disclosed |
| WO-2013128378-A1 | PHENYL ALKANOIC ACID DERIVATIVES AS GPR AGONISTS | Piramal Enterprises Limited (IN) | 2013-09-06 | — | — | WO | disclosed |
| EP-0075146-B1 | BENZYL ESTERS WITH FLUOROSUBSTITUTED ETHER GROUPS, PROCESS FOR THEIR PREPARATION AND THEIR UTILISATION AS INSECTICIDES | BAYER AG (DE) | 1985-10-23 | — | — | EP | disclosed |
| EP-0075146-A1 | Benzyl esters with fluorosubstituted ether groups, process for their preparation and their utilisation as insecticides | BAYER AG (DE) | 1983-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10316035-B2 | Triazolopyridine inhibitors of myeloperoxidase | EPX, MPO, SERPINB1 | GPR3 3165/4885MPO 2/4885PDE2A 193/4885 |
| US-20200347071-A1 | AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS | RIPK1, RIPK2, RIPK4 | GPR3 2258/4885MPO 2427/4885PDE2A 3135/4885 |
| US-20180244671-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | EPX, MPO, SERPINB1 | GPR3 3165/4885MPO 2/4885PDE2A 193/4885 |
| US-20250034108-A1 | SODIUM CHANNEL BLOCKERS | SCN5A, SCN2B, SCN1B | GPR3 1956/4885MPO 3635/4885PDE2A 399/4885 |
| US-20150072969-A1 | PHENYL ALKANOIC ACID DERIVATIVES AS GPR AGONISTS | GPR55, GPR65, GPR35 | GPR3 5/4885MPO 4851/4885PDE2A 2247/4885 |
| US-11618753-B2 | Aminopyrrolotriazines as kinase inhibitors | RIPK1, RIPK2, RIPK4 | GPR3 2258/4885MPO 2427/4885PDE2A 3135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.